Peer-reviewed veterinary case report
Detecting BIRC5 protein in dog mammary tumor blood samples
By Jena, Subas Chandra et al.·Published in Scientific reports·2019·ICAR-Indian Veterinary Research Institute [Deemed University], India·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Surface plasmon resonance immunosensor for label-free detection of BIRC5 biomarker in spontaneously occurring canine mammary tumours.
- Species:
- dog
Plain-English summary
A new test has been developed to detect a specific protein called BIRC5 in the blood of dogs with mammary tumors, which are a type of cancer. This test showed that dogs with these tumors had higher levels of BIRC5 compared to healthy dogs or those with other health issues. The test was able to identify the protein with high accuracy, making it a promising tool for diagnosing and managing canine mammary tumors. This could help veterinarians provide better care for affected dogs in the future.
People also search for: dog mammary tumor symptoms · BIRC5 test for dogs · canine cancer blood test
Abstract
We report detection of Baculoviral inhibitor of apoptosis repeat containing-5 (BIRC5) protein biomarker in dog serum by label-free surface plasmon resonance (SPR) immunosensor. Initially, overexpression of BIRC5 in canine mammary tumour (CMT) tissues was confirmed by real-time PCR. Recombinant BIRC5 was produced and protein specific antibodies developed in guinea pig specifically reacted with native protein in immunohistochemistry and immunocytochemistry. SPR immunosensor was developed by fabricating anti-BIRC5 antibodies on gold sensor disc. The equilibrium dissociation constant, (K = k/k) was 12.1 × 10M; which indicates that antibodies are of high affinity with sensitivity in picomolar range. The SPR assay could detect as low as 6.25 pg/ml of BIRC5 protein in a calibration experiment (r = 0.9964). On testing real clinical samples, 95% specificity and 73.33% sensitivity were recorded. The average amount of serum BIRC5 in dogs with CMT was 110.02 ± 9.77 pg/ml; whereas, in non-cancerous disease conditions, 44.79 ± 4.28 pg/ml and in healthy dog sera 30.28 ± 2.99 pg/ml protein was detected. The SPR immunosensor for detection of BIRC5 in dog sera is reported for the first time and this may find prognostic and diagnostic applications in management of CMT. In future, 'on-site' sensors can be developed using this technique for near-patient testing.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31530877/